NCT01980654 - Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions

Follicular LymphomaB-cell LymphomaNon-Hodgkin's Lymphoma

Interventions

DRUG

Ibrutinib

All subjects will receive 560 mg of Ibrutinib orally.

DRUG

rituximab

All subjects will receive rituximab 375 mg/m2 intravenously

Trial Locations (12)

Memorial Sloan-Kettering Cancer Center, New York

Weill Cornell Medical College New York-Presbyterian Hospital, New York

Southeastern Regional Medical Center, Newnan

Tennessee Oncology, PLLC The Sarah Cannon Research Institute, Nashville

Mid-Ohio Oncology/ Hematology Inc, Columbus

Community Health Network Community Regional Cancer Center North, Indianapolis

The University of Texas MD Anderson Cancer Center, Houston

Comprehensive Cancer Centers of Nevada, Henderson

UCLA Medical Center, Los Angeles

City of Hope, Duarte

Providence Saint Joseph Medical Center, Burbank

Stanford University, Stanford Care Center, Stanford